# **Special Issue**

# 20th Anniversary of Pharmaceuticals—Advances in Pathophysiology, Pharmacology and Neuroprotection in Glaucoma

## Message from the Guest Editor

It is our great delight and honor to celebrate the 20th Anniversary of *Pharmaceuticals* with a Special Issue on glaucoma, and to invite researchers to contribute a manuscript of original research, review, or short communication. The articles from this Special Issue will be compiled into a dedicated book. As you are aware. the many forms of glaucoma afflict millions of people worldwide. There is still a critical need to better understand the genetics, pathophysiology, and clinical ramifications connected with this heterogeneous optic neuropathy. As leaders in the glaucoma field, I cordially invite you to contribute an original or a review article covering the pathogenesis and/or pharmacology of current treatment modalities for ocular hypertension and glaucoma in an area of your expertise. This can also include neuroprotection for glaucomatous optic neuropathy, animal models, and related topics such as diagnosis, devices, Al, and, of course, the pharmacology of the receptors/enzymes/ion-channels implicated in the disease process or treatment(s).

## **Guest Editor**

Dr. Najam A. Sharif

1. Eye-APC Duke-NUS Medical School, Singapore 169857, Singapore 2. Nanoscope Therapeutics, Inc., Trinity Towers, 2777 N. Stemmons Fwy., Dallas, TX 75207, USA

## Deadline for manuscript submissions

closed (25 December 2024)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/184926

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

